Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Q4 2024 revenue rises to $16.9 million; net loss widens to $150.0 million

Mixed Impact 3 of 5 earnings Written later

Cytokinetics reported fourth-quarter and full-year 2024 results on February 27, 2025. Revenue rose sharply, but the net loss grew in dollar terms, and the company guided to 2025 GAAP operating expense of $670 million to $710 million as it prepares for a possible aficamten launch.

Key points

  • Q4 2024 total revenues were $16.9 million, up from $1.7 million in Q4 2023, benefiting from a $15.0 million upfront payment from Corxel.
  • Q4 2024 net loss was $150.0 million, or $(1.26) per share, versus $136.9 million, or $(1.38) per share, in Q4 2023.
  • Full-year 2024 net loss was $589.5 million, or $(5.26) per share, versus $526.2 million, or $(5.45) per share, in 2023.
  • 2025 GAAP operating expense guidance is $670 million to $710 million; cash, cash equivalents and investments were approximately $1.2 billion at December 31, 2024.

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:05 PM ET
Accession number0000950170-25-029017

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.